Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY2R | P49146 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 3/20 | 0.42 |
| ▸ | CA9 | Q16790 | 3/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21797170 | 0.92 | TLR9 (0.41) | CA12CA9CA1CA2ALDH1A1 | |
| SCHEMBL6423000 | 0.85 | TP53 (0.43) | ALDH1A1GAALMNAL3MBTL1MEN1 | |
| SCHEMBL16055972 | 0.85 | UTS2R (0.43) | CA12CA9CA1CA2ALDH1A1 | |
| SCHEMBL4798346 | 0.85 | KMT2A (0.41) | CA12CA9CA1CA2ALDH1A1 | |
| SCHEMBL4801050 | 0.85 | RAPGEF4 (0.40) | CA12CA9CA1CA2ALDH1A1 | |
| SCHEMBL3274194 | 0.84 | AR (0.57) | CA12CA9CA1CA2ALDH1A1 | |
| SCHEMBL4464947 | 0.83 | CYP19A1 (0.34) | NPY2RCA12CA9CA1CA2 | |
| SCHEMBL4796154 | 0.83 | EGFR (0.41) | NPY2RCA12CA9CA1CA2 | |
| SCHEMBL13848475 | 0.82 | NPY2R (0.47) | NPY2RCA12CA9CA1CA2 | |
| SCHEMBL22730498 | 0.81 | ALDH1A1 (0.43) | CA12CA9CA1CA2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11834417-B2 | Compositions for the treatment of hypertension and/or fibrosis | VECTUS BIOSYSTEMS LIMITED (AU) | 2023-12-05 | — | — | US | disclosed |
| US-20210284612-A1 | Compositions for the Treatment of Hypertension and/or Fibrosis | VECTUS BIOSYSTEMS LIMITED (AU) | 2021-09-16 | — | — | US | disclosed |
| EP-3515895-B1 | IMIDAZOLE DERIVATIVES FOR THE TREATMENT OF HYPERTENSION AND/OR FIBROSIS | VECTUS BIOSYSTEMS LTD (AU) | 2021-08-11 | — | — | EP | disclosed |
| EP-3515895-B1 | IMIDAZOLE DERIVATIVES FOR THE TREATMENT OF HYPERTENSION AND/OR FIBROSIS | VECTUS BIOSYSTEMS LTD (AU) | 2021-08-11 | — | — | EP | disclosed |
| US-11053202-B2 | Compositions for the treatment of hypertension and/or fibrosis | VECTUS BIOSYSTEMS LIMITED (AU) | 2021-07-06 | — | — | US | disclosed |
| EP-3640243-B1 | PIPERAZINE DERIVATIVES FOR THE TREATMENT OF HYPERTENSION AND/OR FIBROSIS | VECTUS BIOSYSTEMS LTD (AU) | 2021-05-26 | — | — | EP | disclosed |
| EP-3640243-B1 | PIPERAZINE DERIVATIVES FOR THE TREATMENT OF HYPERTENSION AND/OR FIBROSIS | VECTUS BIOSYSTEMS LTD (AU) | 2021-05-26 | — | — | EP | disclosed |
| US-20200377474-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2020-12-03 | — | — | US | disclosed |
| US-20200255384-A9 | Compositions for the Treatment of Hypertension and/or Fibrosis | VECTUS BIOSYSTEMS LIMITED (AU) | 2020-08-13 | — | — | US | disclosed |
| EP-3640243-A1 | PIPERAZINE DERIVATIVES FOR THE TREATMENT OF HYPERTENSION AND/OR FIBROSIS | Vectus Biosystems Limited (AU) | 2020-04-22 | — | — | EP | disclosed |
| US-5658903-A | Imidazole compounds, compositions and use | SMITHKLINE BEECHAM CORPORATION (US) | 1997-08-19 | — | — | US | disclosed |
| WO-1997025048-A1 | NOVEL CYCLOALKYL SUBSTITUTED IMIDAZOLES | SMITHKLINE BEECHAM CORPORATION (US) | 1997-07-17 | — | — | WO | disclosed |
| WO-1997025045-A1 | NOVEL SUBSTITUTED IMIDAZOLE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-07-17 | — | — | WO | disclosed |
| WO-1997025047-A1 | NOVEL CYCLOALKYL SUBSTITUDED IMIDAZOLES | SMITHKLINE BEECHAM CORPORATION (US) | 1997-07-17 | — | — | WO | disclosed |
| WO-1997025046-A1 | NOVEL SUBSTITUTED IMIDAZOLE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-07-17 | — | — | WO | disclosed |
| US-5593992-A | CYTOKINE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-01-14 | — | — | US | disclosed |
| US-5593991-A | ANTIINFLAMMATORY, CYTOKINE INHIBITOR, CYCLOOXYGENASE INHIBITOR | SMITHKLINE BEECHAM CORPORATION | 1997-01-14 | — | — | US | disclosed |
| WO-1996040143-A1 | IMIDAZOLE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1996-12-19 | — | — | WO | disclosed |
| WO-1996021452-A1 | CERTAIN 1,4,5-TRI-SUBSTITUTED IMIDAZOLE COMPOUNDS USEFUL AS CYTOKINE | SMITHKLINE BEECHAM CORPORATION (US) | 1996-07-18 | — | — | WO | disclosed |
| WO-1996021654-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1996-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210284612-A1 | Compositions for the Treatment of Hypertension and/or Fibrosis | TGFB1, REN, TGFB2 | NPY2R 1843/4885CA12 3111/4885CA9 2437/4885 |
| US-20200255384-A9 | Compositions for the Treatment of Hypertension and/or Fibrosis | TGFB1, REN, TGFB2 | NPY2R 1843/4885CA12 3111/4885CA9 2437/4885 |
| US-20200377474-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | BRDT, BRD4, BRD3 | NPY2R 1171/4885CA12 1355/4885CA9 1332/4885 |
| US-11834417-B2 | Compositions for the treatment of hypertension and/or fibrosis | TGFB1, REN, TGFB2 | NPY2R 1843/4885CA12 3111/4885CA9 2437/4885 |
| US-11053202-B2 | Compositions for the treatment of hypertension and/or fibrosis | TGFB1, REN, TGFB2 | NPY2R 1843/4885CA12 3111/4885CA9 2437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.